Sage Therapeutics

ZURZUVAE Commercialization And OB/GYN Screening Will Unlock New Opportunities

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

29 Mar 25

Updated

01 May 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

-9.6%

-1.4%

-9.6%

-1.4%

You can edit this narrative until May 12 6:03 AM. Then, changes will post as Updates.

Author's Valuation

US$8.730.6% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates5

Shared on 01 May 25

Fair value Increased 1.73%

Shared on 24 Apr 25

Fair value Decreased 5.40%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 17.3x to 19.1x.

Shared on 09 Apr 25

Fair value Increased 0.78%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 3.11%

AnalystConsensusTarget has increased revenue growth from 58.9% to 66.1%, increased profit margin from 10.5% to 19.3%, decreased future PE multiple from 35.9x to 17.2x and decreased shares outstanding growth rate from 0.0% to 0.0%.

AnalystConsensusTarget Fair Value

US$8.73

0.6% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

25.97%

Biotech revenue growth rate

9.82%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.40%

Calculation

US$17.20m

Earnings '28

40.97x

PE Ratio '28

US$704.52m

Market Cap '28

US$704.52m

Market Cap '28

67.58m

No. shares '28

US$10.43

Share Price '28

US$10.43 Share Price '28

Discounted to 2025 @ 6.40% p.a.

US$8.65

Fair Value '25